Jury Hits AngioDynamics With Patent-Infringement Verdict >ANGO [MarketWatch]
Becton, Dickinson and Company (BDX)
Last becton, dickinson and company earnings: 2/6 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
investors.bd.com
Company Research
Source: MarketWatch
Bard Inc., as a Delaware jury found that some of the medical-device company's implantable port products infringe certain U.S. patents held by the Becton Dickinson Co. unit. In a filing with the U.S. Securities and Exchange Commission, AngioDynamics said it strongly disagrees with the verdict and that it plans to pursue all available remedies and defenses, including post-trial motions and appeals. The Latham, N.Y., company also noted that the issue of damages was bifurcated by the court during the one-week trial and will be decided by a jury in a separate proceeding. The verdict follows last month's loss by AngioDynamics in an antitrust lawsuit against C.R. Bard. In that case, a New York jury dismissed claims by AngioDynamics that Bard restrained competition in the U.S. by tying sales of its tip location systems to sales of its percutaneously inserted central catheters. AngioDynamics has said it is considering an appeal. C.R. Bard initially launched its patent litigation agains
Show less
Read more
Impact Snapshot
Event Time:
BDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDX alerts
High impacting Becton, Dickinson and Company news events
Weekly update
A roundup of the hottest topics
BDX
News
- Closed System Transfer Devices Market Size Expected to Reach USD 5.39 Bn by 2033 | Expansion of Oncology and Infusion Services [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky, LLP Notifies Shareholders of Becton, Dickinson and Company (BDX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Outcome Capital Continues to Expand with the Addition of Industry Veteran Stanislav Glezer, MD MBA [Yahoo! Finance]Yahoo! Finance
- Becton, Dickinson and Company (NYSE: BDX) had its price target raised by analysts at Barclays PLC from $305.00 to $312.00. They now have an "overweight" rating on the stock.MarketBeat
- Injectable Drug Delivery Market Worth $1139.4 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
BDX
Earnings
- 5/2/24 - Beat
BDX
Sec Filings
- 5/6/24 - Form 4
- 5/6/24 - Form 4
- 5/2/24 - Form S-3ASR
- BDX's page on the SEC website